Erste Asset Management GmbH Purchases 910,668 Shares of Ginkgo Bioworks Holdings, Inc. $DNA

Key Points

• Erste Asset Management GmbH increased its stake in Ginkgo Bioworks by 123.2%, holding approximately $9.41 million worth of shares as of the latest SEC filing.
• Various institutional investors, including Barclays PLC and Forbes J M & Co. LLP, also significantly boosted their positions in Ginkgo Bioworks, reflecting growing interest from hedge funds.
• Ginkgo Bioworks reported earnings of ($1.10) per share, surpassing expectations, with a revenue of $49.60 million for the last quarter.

Erste Asset Management GmbH raised its holdings in shares of Ginkgo Bioworks Holdings, Inc. (NYSE:DNA - Free Report) by 123.2% during the first quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 1,650,000 shares of the company's stock after purchasing an additional 910,668 shares during the period. Erste Asset Management GmbH owned 2.84% of Ginkgo Bioworks worth $9,405,000 as of its most recent filing with the Securities and Exchange Commission.

Other institutional investors and hedge funds also recently modified their holdings of the company. US Bancorp DE increased its stake in shares of Ginkgo Bioworks by 43.5% in the 1st quarter. US Bancorp DE now owns 6,302 shares of the company's stock valued at $36,000 after acquiring an additional 1,911 shares during the last quarter. Mercer Global Advisors Inc. ADV bought a new position in shares of Ginkgo Bioworks during the 4th quarter worth approximately $116,000. CWM LLC boosted its holdings in shares of Ginkgo Bioworks by 667.6% in the 1st quarter. CWM LLC now owns 12,274 shares of the company's stock valued at $70,000 after buying an additional 10,675 shares during the last quarter. Fox Run Management L.L.C. acquired a new stake in shares of Ginkgo Bioworks in the 1st quarter valued at approximately $76,000. Finally, Green Alpha Advisors LLC boosted its holdings in shares of Ginkgo Bioworks by 31.7% in the 1st quarter. Green Alpha Advisors LLC now owns 18,470 shares of the company's stock valued at $105,000 after buying an additional 4,449 shares during the last quarter. 78.63% of the stock is owned by institutional investors.

Ginkgo Bioworks Price Performance

Shares of Ginkgo Bioworks stock traded up $0.15 during midday trading on Tuesday, reaching $12.20. The company had a trading volume of 561,420 shares, compared to its average volume of 1,523,414. Ginkgo Bioworks Holdings, Inc. has a fifty-two week low of $5.00 and a fifty-two week high of $16.85. The stock has a fifty day moving average price of $11.61 and a 200 day moving average price of $9.32. The firm has a market cap of $722.30 million, a PE ratio of -2.08 and a beta of 1.50.

Ginkgo Bioworks (NYSE:DNA - Get Free Report) last issued its quarterly earnings results on Thursday, August 7th. The company reported ($1.10) earnings per share (EPS) for the quarter, beating the consensus estimate of ($1.44) by $0.34. Ginkgo Bioworks had a negative return on equity of 43.25% and a negative net margin of 136.56%.The firm had revenue of $49.60 million for the quarter, compared to analyst estimates of $41.60 million. Ginkgo Bioworks has set its FY 2025 guidance at EPS. As a group, sell-side analysts forecast that Ginkgo Bioworks Holdings, Inc. will post -10.02 EPS for the current year.

Analysts Set New Price Targets

Several equities research analysts have issued reports on DNA shares. BTIG Research raised their price target on Ginkgo Bioworks from $6.00 to $9.00 and gave the company a "sell" rating in a report on Monday. Cowen restated a "buy" rating on shares of Ginkgo Bioworks in a research report on Friday, August 8th. Two research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company. According to MarketBeat, Ginkgo Bioworks presently has a consensus rating of "Hold" and a consensus price target of $9.50.

Ginkgo Bioworks Company Profile

Ginkgo Bioworks Holdings, Inc, together with its subsidiaries, develops platform for cell programming in the United States. Its platform is used to program cells to enable biological production of products, such as novel therapeutics, food ingredients, and chemicals derived from petroleum. It serves pharma and biotech, agriculture, industrial and environment, food and nutrition, consumer and technology, and government and defense industries.